Search

Your search keyword '"Matulonis, Ursula A."' showing total 1,409 results
Start Over Author "Matulonis, Ursula A."
1,409 results on '"Matulonis, Ursula A."'

1. Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib

Author

Barnicle, Alan, Ray-Coquard, Isabelle, Rouleau, Etienne, Cadoo, Karen, Simpkins, Fiona, Aghajanian, Carol, Leary, Alexandra, Poveda, Andrés, Lheureux, Stephanie, Pujade-Lauraine, Eric, You, Benoit, Ledermann, Jonathan, Matulonis, Ursula, Gourley, Charlie, Timms, Kirsten M., Lai, Zhongwu, Hodgson, Darren R., Elks, Cathy E., Dearden, Simon, Egile, Coumaran, Lao-Sirieix, Pierre, Harrington, Elizabeth A., and Brown, Jessica S.

Published
2024
Full Text
View/download PDF

2. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary

Author

Moore, Kathleen N., Lorusso, Domenica, Oaknin, Ana, Oza, Amit, Colombo, Nicoletta, Van Gorp, Toon, O'Malley, David M., Banerjee, Susana, Murphy, Conleth G., Harter, Philipp, Konecny, Gottfried E., Pautier, Patricia, Method, Michael, Wang, Yuemei, Coleman, Robert L., Birrer, Michael, and Matulonis, Ursula A.

Published
2024
Full Text
View/download PDF

5. Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial

Author

Pozzar, Rachel A., Enzinger, Andrea C., Howard, Catherine, Tavormina, Anna, Matulonis, Ursula A., Campos, Susana, Liu, Joyce F., Horowitz, Neil, Konstantinopoulos, Panagiotis A., Krasner, Carolyn, Wall, Jaclyn A., Sciacca, Kate, Meyer, Larissa A., Lindvall, Charlotta, and Wright, Alexi A.

Published
2024
Full Text
View/download PDF

6. A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib

Author

Liu, Joyce F., Xiong, Niya, Wenham, Robert M., Wahner-Hendrickson, Andrea, Armstrong, Deborah K., Chan, Nancy, O'Malley, David M., Lee, Jung-Min, Penson, Richard T., Cristea, Mihaela C., Abbruzzese, James L., Matsuo, Koji, Olawaiye, Alexander B., Barry, William T., Cheng, Su-Chun, Polak, Madeline, Swisher, Elizabeth M., Shapiro, Geoffrey I., Kohn, Elise C., Ivy, S. Percy, and Matulonis, Ursula A.

Published
2024
Full Text
View/download PDF

8. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Author

Richardson, Debra L., Moore, Kathleen N., Vergote, Ignace, Gilbert, Lucy, Martin, Lainie P., Mantia-Smaldone, Gina M., Castro, Cesar M., Provencher, Diane, Matulonis, Ursula A., Stec, James, Wang, Yuemei, Method, Michael, and O'Malley, David M.

Published
2024
Full Text
View/download PDF

9. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.

Author

Matulonis, Ursula A, Huang, Helen Q, Filiaci, Virginia L, Randall, Marcus, DiSilvestro, Paul A, Moxley, Katherine M, Fowler, Jeffrey M, Powell, Matthew A, Spirtos, Nick M, Tewari, Krishnansu S, Richards, William E, Nakayama, John M, Mutch, David G, Miller, David S, Matei, Daniela, and Wenzel, Lari B

Subjects
Humans, Endometrial Neoplasms, Gastrointestinal Diseases, Peripheral Nervous System Diseases, Cisplatin, Paclitaxel, Carboplatin, Neoplasm Staging, Disease-Free Survival, Chemotherapy, Adjuvant, Quality of Life, Female, Chemoradiotherapy, Adjuvant, Patient Reported Outcome Measures, Functional Status, Chemotherapy, Combined radiation therapy, Endometrial cancer, Patient reported outcomes, Quality of life, Patient Safety, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis
Abstract

IntroductionChemotherapy plus radiation (Cis-RT + CP) did not demonstrate superiority in prolonging relapse-free survival compared to chemotherapy alone in patients with stage III or IVA endometrial carcinoma. The impact of treatment on quality of life (QOL), neurotoxicity (NTX) and psychometric properties of the gastrointestinal (GI) symptoms subscale during treatment and up to 1 year are described herein.MethodsQOL assessments were scheduled at baseline, 6 weeks (post completion of RT (Cis-RT + CP) or prior to cycle 3 (CP)), then 18 weeks (end of treatment) and 70 weeks (1 year after the end of treatment) after starting treatment. QOL instruments included the FACT-En TOI, FACT/GOG-neurotoxicity (Ntx) subscale (short), and the gastrointestinal (GI) symptoms subscale.ResultsAt the end of treatment, patients receiving Cis-RT + CP reported a statistically significant decreased QOL when compared to CP. The decline in QOL was reflected in physical well-being, functional well-being, and endometrial cancer specific concerns, but the minimally important differences (MID) were not considered clinically meaningful. Patients in both groups reported increased chemotherapy-induced Ntx symptoms with the CP group having worse scores and reaching peak symptoms at the time of chemotherapy completion. Patients on Cis-RT + CP reported statistically significantly worse GI symptoms after radiation therapy compared to patients on CP, this occurred across assessment intervals, though the MID was not meaningful. Psychometric evaluations indicated that the GI symptom scale is reliable, valid, and responsive to change.ConclusionsPROs indicate that the chemoradiotherapy group experienced worse HRQoL and GI toxicity compared to patients randomized to chemotherapy alone for locally advanced endometrial cancer though based on the MID, these were not clinically meaningful differences. The GI symptom subscale was a reliable and valid scale that has value for future trials.Trial registrationNCT00942357.

Published
2022

10. Predicting master transcription factors from pan-cancer expression data

Author

Reddy, Jessica, Fonseca, Marcos AS, Corona, Rosario I, Nameki, Robbin, Segato Dezem, Felipe, Klein, Isaac A, Chang, Heidi, Chaves-Moreira, Daniele, Afeyan, Lena K, Malta, Tathiane M, Lin, Xianzhi, Abbasi, Forough, Font-Tello, Alba, Sabedot, Thais, Cejas, Paloma, Rodríguez-Malavé, Norma, Seo, Ji-Heui, Lin, De-Chen, Matulonis, Ursula, Karlan, Beth Y, Gayther, Simon A, Pasaniuc, Bogdan, Gusev, Alexander, Noushmehr, Houtan, Long, Henry, Freedman, Matthew L, Drapkin, Ronny, Young, Richard A, Abraham, Brian J, and Lawrenson, Kate

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Ovarian Cancer, Cancer, Orphan Drug, Women's Health, Rare Diseases, Genetics, Cancer Genomics, Human Genome, 1.1 Normal biological development and functioning, 2.1 Biological and endogenous factors
Abstract

Critical developmental “master transcription factors” (MTFs) can be subverted during tumorigenesis to control oncogenic transcriptional programs. Current approaches to identifying MTFs rely on ChIP-seq data, which is unavailable for many cancers. We developed the CaCTS (Cancer Core Transcription factor Specificity) algorithm to prioritize candidate MTFs using pan-cancer RNA sequencing data. CaCTS identified candidate MTFs across 34 tumor types and 140 subtypes including predictions for cancer types/subtypes for which MTFs are unknown, including e.g. PAX8, SOX17, and MECOM as candidates in ovarian cancer (OvCa). In OvCa cells, consistent with known MTF properties, these factors are required for viability, lie proximal to superenhancers, co-occupy regulatory elements globally, co-bind loci encoding OvCa biomarkers, and are sensitive to pharmacologic inhibition of transcription. Our predictions of MTFs, especially for tumor types with limited understanding of transcriptional drivers, pave the way to therapeutic targeting of MTFs in a broad spectrum of cancers.

Published
2021

13. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

Author

Konstantinopoulos, Panagiotis A., Cheng, Su-Chun, Lee, Elizabeth K., da Costa, Alexandre André B.A., Gulhan, Doga, Wahner Hendrickson, Andrea E., Kochupurakkal, Bose, Kolin, David L., Kohn, Elise C., Liu, Joyce F., Penson, Richard T., Stover, Elizabeth H., Curtis, Jennifer, Sawyer, Hannah, Polak, Madeline, Chowdhury, Dipanjan, DʼAndrea, Alan D., Färkkilä, Anniina, Shapiro, Geoffrey I., and Matulonis, Ursula A.

Published
2024
Full Text
View/download PDF

14. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

Author

Ledermann, Jonathan A., Shapira-Frommer, Ronnie, Santin, Alessandro D., Lisyanskaya, Alla S., Pignata, Sandro, Vergote, Ignace, Raspagliesi, Francesco, Sonke, Gabe S., Birrer, Michael, Provencher, Diane M., Sehouli, Jalid, Colombo, Nicoletta, González-Martín, Antonio, Oaknin, Ana, Ottevanger, P.B., Rudaitis, Vilius, Kobie, Julie, Nebozhyn, Michael, Edmondson, Mackenzie, Sun, Yuan, Cristescu, Razvan, Jelinic, Petar, Keefe, Stephen M., and Matulonis, Ursula A.

Published
2023
Full Text
View/download PDF

20. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma

Author

Arend, Rebecca, Dholakia, Jhalak, Castro, Cesar, Matulonis, Ursula, Hamilton, Erika, Jackson, Camille Gunderson, LyBarger, Kristopher, Goodman, Howard M., Duska, Linda R., Mahdi, Haider, ElNaggar, Adam C., Kagey, Michael H., Liu, Amy, Piper, Diane, Barroilhet, Lisa M., Bradley, William, Sachdev, Jasgit, Sirard, Cynthia A., O'Malley, David M., and Birrer, Michael

Published
2023
Full Text
View/download PDF

21. A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors

Author

Campos, Susana, Matulonis, Ursula, Berlin, Suzanne, Horowitz, Neil, Liu, Joyce, Krasner, Carolyn, Hang, Lee, Zarwan, Corrine, Barry, William, Colella, Tina, Whalen, Christen, Shoni, Melina, Lundquist, Christine, Birrer, Michael J., and Penson, Richard

Published
2022
Full Text
View/download PDF

24. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

Author

Matei, Daniela, Filiaci, Virginia, Randall, Marcus, Mutch, David, Steinhoff, Margaret, DiSilvestro, Paul, Moxley, Katherine, Kim, Yong, Powell, Matthew, OMalley, David, Spirtos, Nick, Small, William, Richards, William, Nakayama, John, Matulonis, Ursula, Huang, Helen, Miller, David, and Tewari, Krishnansu

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Adjuvant, Chemotherapy, Adjuvant, Disease-Free Survival, Endometrial Neoplasms, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Neoplasm, Residual, Prognosis, Quality of Life, Recurrence, Statistics, Nonparametric, Treatment Outcome
Abstract

BACKGROUND: Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. METHODS: In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life. RESULTS: Of the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, the Kaplan-Meier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 to 0.66) than chemotherapy alone, but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group. CONCLUSIONS: Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.).

Published
2019

25. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

Author

Konstantinopoulos, Panagiotis A., Cheng, Su-Chun, Supko, Jeffrey G., Polak, Madeline, Wahner-Hendrickson, Andrea E., Ivy, S. Percy, Bowes, Brittany, Sawyer, Hannah, Basada, Patrice, Hayes, Martin, Curtis, Jennifer, Horowitz, Neil, Wright, Alexi A., Campos, Susana M., Ivanova, Elena V., Paweletz, Cloud P., Palakurthi, Sangeetha, Liu, Joyce F., D’Andrea, Alan D., Gokhale, Prafulla C., Chowdhury, Dipanjan, Matulonis, Ursula A., and Shapiro, Geoffrey I.

Published
2022
Full Text
View/download PDF

26. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

Author

Wang, Qiwei, Bergholz, Johann S., Ding, Liya, Lin, Ziying, Kabraji, Sheheryar K., Hughes, Melissa E., He, Xiadi, Xie, Shaozhen, Jiang, Tao, Wang, Weihua, Zoeller, Jason J., Kim, Hye-Jung, Roberts, Thomas M., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Dillon, Deborah A., Winer, Eric P., Lin, Nancy U., and Zhao, Jean J.

Published
2022
Full Text
View/download PDF

27. Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial

Author

Coleman, Robert L, primary, Lorusso, Domenica, additional, Oaknin, Ana, additional, Cecere, Sabrina Chiara, additional, Denys, Hannelore, additional, Colombo, Nicoletta, additional, van Gorp, Toon, additional, Konner, Jason A, additional, Romeo Marin, Margarita, additional, Harter, Philipp, additional, Murphy, Conleth, additional, Wang, Yuemei, additional, Esteves, Brooke, additional, Method, Michael, additional, and Matulonis, Ursula, additional

Published
2024
Full Text
View/download PDF

28. Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).

Author

Konstantinopoulos, Panagiotis A., primary, Cai, Mingyang, additional, Lee, Elizabeth Katherine, additional, Xiong, Niya, additional, Krasner, Carolyn N., additional, Campos, Susana M., additional, Liu, Joyce F., additional, Horowitz, Neil S., additional, Wright, Alexi A., additional, Shea, Meghan, additional, Bouberhan, Sara, additional, Penson, Richard T., additional, Yeku, Oladapo O., additional, Sawyer, Hannah, additional, Hayes, Martin, additional, Polak, Madeline, additional, Castro, Cesar Martin, additional, Cheng, SuChun, additional, Weipert, Caroline M., additional, and Matulonis, Ursula A., additional

Published
2024
Full Text
View/download PDF

29. BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).

Author

Juric, Dejan, primary, Patel, Manish R., additional, Duska, Linda R., additional, Jhaveri, Komal L., additional, Henick, Brian S., additional, Matulonis, Ursula A., additional, Munster, Pamela N., additional, Birrer, Michael J., additional, Moore, Kathleen N., additional, Curigliano, Giuseppe, additional, Li, Chia-Cheng, additional, Guo, Jian, additional, He, Kevin, additional, Wu, Rentian, additional, Tamulevich, Sam, additional, Rinne, Mikael, additional, and Yap, Timothy A., additional

Published
2024
Full Text
View/download PDF

30. Supplementary Material 1 from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Author

Corcoran, Ryan B., primary, Do, Khanh T., primary, Kim, Jeong E., primary, Cleary, James M., primary, Parikh, Aparna R., primary, Yeku, Oladapo O., primary, Xiong, Niya, primary, Weekes, Colin D., primary, Veneris, Jennifer, primary, Ahronian, Leanne G., primary, Mauri, Gianluca, primary, Tian, Jun, primary, Norden, Bryanna L., primary, Michel, Alexa G., primary, Van Seventer, Emily E., primary, Siravegna, Giulia, primary, Camphausen, Kyle, primary, Chi, Gary, primary, Fetter, Isobel J., primary, Brugge, Joan S., primary, Chen, Helen, primary, Takebe, Naoko, primary, Penson, Richard T., primary, Juric, Dejan, primary, Flaherty, Keith T., primary, Sullivan, Ryan J., primary, Clark, Jeffrey W., primary, Heist, Rebecca S., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, and Shapiro, Geoffrey I., primary

Published
2024
Full Text
View/download PDF

32. Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Author

Tjokrowidjaja, Angelina, Friedlander, Michael, Lord, Sarah J., Asher, Rebecca, Rodrigues, Manuel, Ledermann, Jonathan A., Matulonis, Ursula A., Oza, Amit M., Bruchim, Ilan, Huzarski, Tomasz, Gourley, Charlie, Harter, Philipp, Vergote, Ignace, Scott, Clare L., Meier, Werner, Shapira-Frommer, Ronnie, Milenkova, Tsveta, Pujade-Lauraine, Eric, Gebski, Val, and Lee, Chee K.

Published
2021
Full Text
View/download PDF

36. Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors

Author

Schrier, Elizabeth, Xiong, Niya, Thompson, Embree, Poort, Hanneke, Schumer, Susan, Liu, Joyce F., Krasner, Carolyn, Campos, Susana M., Horowitz, Neil S., Feltmate, Colleen, Konstantinopoulos, Panagiotis A., Dinardo, Margaret M, Tayob, Nabihah, Matulonis, Ursula A., Patel, Mitesh, and Wright, Alexi A.

Published
2021
Full Text
View/download PDF

37. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

Author

Rafii, Saeed, Gourley, Charlie, Kumar, Rajiv, Geuna, Elena, Ang, Joo Ern, Rye, Tzyvia, Chen, Lee-May, Shapira-Frommer, Ronnie, Friedlander, Michael, Matulonis, Ursula, De Greve, Jacques, Oza, Amit M, Banerjee, Susana, Molife, L Rhoda, Gore, Martin E, Kaye, Stan B, and Yap, Timothy A

Subjects
Rare Diseases, Orphan Drug, Cancer, Ovarian Cancer, Clinical Research, Genetics, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Agents, BRCA1 Protein, BRCA2 Protein, Female, Germ-Line Mutation, Humans, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Ovarian Neoplasms, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerase Inhibitors, Prognosis, Recurrence, Survival Analysis, Treatment Outcome, PARP inhibitor, olaparib, BRCA, ovarian cancer, predictive biomarkers, Oncology and Carcinogenesis
Abstract

BackgroundThe PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in only approximately 40% of patients and the impact of baseline clinical factors on response to treatment remains unclear. Although platinum sensitivity has been suggested as a marker of response to PARP inhibitors, patients with platinum-resistant disease still respond to olaparib.Results108 patients with advanced BRCA1/2 mutation ovarian cancers were included. The interval between the end of the most recent platinum chemotherapy and PARPi (PTPI) was used to predict response to olaparib independent of conventional definition of platinum sensitivity. RECIST complete response (CR) and partial response (PR) rates were 35% in patients with platinum-sensitive versus 13% in platinum-resistant (p

Published
2017

44. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial

Author

Lee, Elizabeth K., Xiong, Niya, Cheng, Su-Chun, Barry, William T., Penson, Richard T., Konstantinopoulos, Panagiotis A., Hoffman, Mark A., Horowitz, Neil, Dizon, Don S., Stover, Elizabeth H., Wright, Alexi A., Campos, Susana M., Krasner, Carolyn, Morrissey, Stephanie, Whalen, Christin, Quinn, Roxanne, Matulonis, Ursula A., and Liu, Joyce F.

Published
2020
Full Text
View/download PDF

45. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Author

Konstantinopoulos, Panagiotis A, Cheng, Su-Chun, Wahner Hendrickson, Andrea E, Penson, Richard T, Schumer, Susan T, Doyle, L Austin, Lee, Elizabeth K, Kohn, Elise C, Duska, Linda R, Crispens, Marta A, Olawaiye, Alexander B, Winer, Ira S, Barroilhet, Lisa M, Fu, Siqing, McHale, Michael T, Schilder, Russell J, Färkkilä, Anniina, Chowdhury, Dipanjan, Curtis, Jennifer, Quinn, Roxanne S, Bowes, Brittany, D'Andrea, Alan D, Shapiro, Geoffrey I, and Matulonis, Ursula A

Published
2020
Full Text
View/download PDF

46. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Author

O'Malley, David M., Matulonis, Ursula A., Birrer, Michael J., Castro, Cesar M., Gilbert, Lucy, Vergote, Ignace, Martin, Lainie P., Mantia-Smaldone, Gina M., Martin, Antonio González, Bratos, Raquel, Penson, Richard T., Malek, Karim, and Moore, Kathleen N.

Published
2020
Full Text
View/download PDF

48. Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer

Author

Konstantinopoulos, Panagiotis A., primary, Xiong, Niya, additional, Krasner, Carolyn, additional, Liu, Joyce F., additional, Sawyer, Hannah, additional, Polak, Madeline, additional, Needham, Hope, additional, Geddes, Megan, additional, Koppermann, Lani, additional, Shea, Meghan, additional, Castro, Cesar, additional, Cheng, Su-Chun, additional, Matulonis, Ursula A., additional, and Lee, Elizabeth K., additional

Published
2024
Full Text
View/download PDF

49. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Author

Corcoran, Ryan B., primary, Do, Khanh T., additional, Kim, Jeong E., additional, Cleary, James M., additional, Parikh, Aparna R., additional, Yeku, Oladapo O., additional, Xiong, Niya, additional, Weekes, Colin D., additional, Veneris, Jennifer, additional, Ahronian, Leanne G., additional, Mauri, Gianluca, additional, Tian, Jun, additional, Norden, Bryanna L., additional, Michel, Alexa G., additional, Van Seventer, Emily E., additional, Siravegna, Giulia, additional, Camphausen, Kyle, additional, Chi, Gary, additional, Fetter, Isobel J., additional, Brugge, Joan S., additional, Chen, Helen, additional, Takebe, Naoko, additional, Penson, Richard T., additional, Juric, Dejan, additional, Flaherty, Keith T., additional, Sullivan, Ryan J., additional, Clark, Jeffrey W., additional, Heist, Rebecca S., additional, Matulonis, Ursula A., additional, Liu, Joyce F., additional, and Shapiro, Geoffrey I., additional

Published
2024
Full Text
View/download PDF

50. Abstract A011: An implantable microdevice to interrogate responses to therapy in ovarian cancer

Author

Stover, Elizabeth H., primary, Tatarova, Zuzana, additional, Bhagavatula, Sharath K., additional, Dominas, Christine, additional, Polak, Madeline, additional, Rabbitt, Alexis, additional, Gardner, Jeanette, additional, MacNeill, Kim, additional, Azzolini, Natalie, additional, Ahn, Sebastian, additional, Worley, Michael J., additional, Elias, Kevin M., additional, Kolin, David L., additional, Liu, Joyce F., additional, Matulonis, Ursula A., additional, Silverman, Stuart G., additional, Horowitz, Neil S., additional, and Jonas, Oliver, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results